NCT00470665View on ClinicalTrials.gov

Study Comparing Sirolimus/Prograf vs Sirolimus/CsA in High-Risk Renal Transplant Recipients

PHASE3CompletedINTERVENTIONAL
Enrollment

460

Participants

Timeline

Start Date

August 31, 2002

Study Completion Date

July 31, 2004

Conditions
Renal Allograft Recipients
Interventions
DRUG

Rapamune

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00470665 - Study Comparing Sirolimus/Prograf vs Sirolimus/CsA in High-Risk Renal Transplant Recipients | Biotech Hunter | Biotech Hunter